Evidence map›Paper›PMID 42365197›Full record

ArticleInternational journal of clinical oncology2026

Pretreatment serum vitamin D levels predict the therapeutic efficacy of atezolizumab plus bevacizumab therapy in advanced hepatocellular carcinoma: a multicenter analysis.

Takanori Suzuki, Kentaro Matsuura, Satoshi Narahara, Kohei Okayama, Fumihiro Okumura, Satoshi Sobue, Kiyoto Narita, Tsutomu Mizoshita, Hiromu Kondo, Yoshihide Kimura and 11 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in International journal of clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Takanori SuzukiDepartment of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, 1, Kawasumi, Mizuho, Nagoya, Aichi, 467-8601, Japan.
Kentaro MatsuuraDepartment of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, 1, Kawasumi, Mizuho, Nagoya, Aichi, 467-8601, Japan. matsuura@med.nagoya-cu.ac.jp.
Satoshi NaraharaDepartment of Gastroenterology and Hepatology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.
Kohei OkayamaDepartment of Gastroenterology, Gifu Prefectural Tajimi Hospital, Gifu, Japan.
Fumihiro OkumuraDepartment of Gastroenterology, Gifu Prefectural Tajimi Hospital, Gifu, Japan.
Satoshi SobueDepartment of Gastroenterology, Kasugai Municipal Hospital, Kasugai, Japan.
Kiyoto NaritaDepartment of Gastroenterology, Toyokawa City Hospital, Toyokawa, Japan.
Tsutomu MizoshitaDepartment of Gastroenterology, Toyokawa City Hospital, Toyokawa, Japan.
Hiromu KondoDepartment of Gastroenterology, Nagoya City University West Medical Center, Nagoya, Japan.
Yoshihide KimuraDepartment of Gastroenterology, Nagoya City University West Medical Center, Nagoya, Japan.
Daisuke KatoDepartment of Gastroenterology, Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital, Nagoya, Japan.
Katsumi HayashiDepartment of Gastroenterology, Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital, Nagoya, Japan.
Haruki UojimaDepartment of Gastroenterology and Hepatology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.
Mayumi HojoDepartment of Gastroenterology and Hepatology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.
Shuko MurakamiDepartment of Gastroenterology and Hepatology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.
Takako InoueDepartment of Clinical Laboratory Medicine, Nagoya City University Hospital, Nagoya, Japan.
Hayato KawamuraDepartment of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, 1, Kawasumi, Mizuho, Nagoya, Aichi, 467-8601, Japan.
Kei FujiwaraDepartment of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, 1, Kawasumi, Mizuho, Nagoya, Aichi, 467-8601, Japan.
Shunsuke NojiriDepartment of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, 1, Kawasumi, Mizuho, Nagoya, Aichi, 467-8601, Japan.
Hiromi KataokaDepartment of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, 1, Kawasumi, Mizuho, Nagoya, Aichi, 467-8601, Japan.
Yasuhito TanakaDepartment of Gastroenterology and Hepatology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.

Funding

Grant-in Aid for Research in Nagoya City University 2522103KAKENHI JP23K07359Takeda Science Foundation Takeda Science FoundationThe Nitto Foundation The Nitto FoundationTOYOAKI SCHOLARSHIP FOUNDATION TOYOAKI SCHOLARSHIP FOUNDATIONUehara Memorial Foundation Uehara Memorial Foundation
6 · The paper itself

Abstract

backgroundIncreasing evidence indicates that vitamin D has anticancer effects. However, there are very limited data regarding the relationship between vitamin D levels and the efficacy or prognosis by atezolizumab plus bevacizumab (ATZ/BEV) for hepatocellular carcinoma (HCC). We sought to investigate this.

methodsThis study included 142 HCC patients who were treated with ATZ/BEV as the first-line of systemic chemotherapy. Their initial treatment responses were evaluated using dynamic computed tomography or magnetic resonance imaging. Serum levels of 25-hydroxyvitamin D (vitamin D) were measured before treatment, and their associations with treatment efficacy and prognosis were analyzed.

resultsPretreatment vitamin D levels tended to be lower in patients who showed progressive disease (PD) at the initial response assessment than in those without PD (P = 0.098). Receiver operating curve analysis of pretreatment serum vitamin D levels for discriminating non-PD and PD at the initial therapeutic response yielded an area under the curve of 0.611, and the optimal cutoff value was determined to be 17.8 ng/mL. In addition, this cutoff value effectively stratified patients according to overall survival (OS) (high vs. low: not reached vs. 27.0 months, P = 0.022). Multivariate analysis showed that modified albumin-bilirubin grade (≥ 2a) (HR = 2.06; P = 0.018) and high serum vitamin D levels (≥ 17.8 ng/ml) (HR = 0.58; P = 0.046) were independently associated with OS.

conclusionsSerum vitamin D levels before treatment may serve as a predictive biomarker for the prognosis in patients treated with ATZ/BEV for advanced HCC.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsBevacizumabCarcinoma, HepatocellularLiver NeoplasmsVitamin DAdultAgedAntibodies, Monoclonal, HumanizedFemaleHumansMaleMiddle AgedPrognosisTreatment Outcome25-hydroxyvitamin DAntibodies, Monoclonal, HumanizedatezolizumabBevacizumabVitamin DAtezolizumabBevacizumabHepatocellular carcinomaVitamin D

Identifiers

PMID42365197

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.